IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer’s Disease

Trial data can be implemented in different ways across health-economic models leading to large variation in model predictions. We recommend (1) addressing the choice of outcome measure and treatment effectiveness assumptions in sensitivity analysis, (2) a standardized reporting table for model predictions, and (3) exploring the use of registries for future AD treatments measuring long-term disease progression to reduce uncertainty of extrapolating short-term trial results by health-economic models.

Authors

Institutions

Publication Details

Journal
Value in Health
Published
2024-10-08
DOI
https://doi.org/10.1016/j.jval.2024.09.006
Citations
4
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
4.52

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer’s Disease

Peter Pemberton‐Ross, Linus Jönsson, Anders Gustavsson, Jakub Hlávka et al.
4 citations
Value in Health
Health Systems, Economic Evaluations, Quality of Life
4.52
article

IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer’s Disease

Peter Pemberton‐Ross, Linus Jönsson, Anders Gustavsson, Jakub Hlávka, Eldon Spackman, Lars Lau Rakêt, Ashley Tate, Sandar Aye, William L. Herring, Myriam Soto‐Gordoa, F. Kamgar, M. Urbich, Javier Mar, Anders Sköldunger, Chiara C. Brück, Bengt Winblad, Ron L. H. Handels, Anders Wimo, Chelsea Bedrejo Stellick, Colin Green, Robert M. Anderson, Yifan Wei, Inge de Kok
article en
4 citations

Abstract

Trial data can be implemented in different ways across health-economic models leading to large variation in model predictions. We recommend (1) addressing the choice of outcome measure and treatment effectiveness assumptions in sensitivity analysis, (2) a standardized reporting table for model predictions, and (3) exploring the use of registries for future AD treatments measuring long-term disease progression to reduce uncertainty of extrapolating short-term trial results by health-economic models.

Value in HealthVol. 28(4)
Karolinska University Hospital (SE), Mondragon Unibertsitatea (ES), Lund University (SE), Erasmus MC (NL), Karolinska Institutet (SE), RTI Health Solutions (US), Biogen (Switzerland) (CH)
Karolinska Institutet, National Institutes of Health
Openalex Percentile: Top 5%
Health Systems, Economic Evaluations, Quality of Life
4.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.